Published in J Neurol on April 18, 2013
A clinico-epidemiological study of cognitive function status of community-dwelling elderly. Indian J Psychiatry (2014) 0.86
Neurological update: dementia. J Neurol (2014) 0.75
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol (2007) 18.62
Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med (2012) 14.14
Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol (2010) 8.74
Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells. Nature (2012) 5.47
Exosome-associated tau is secreted in tauopathy models and is selectively phosphorylated in cerebrospinal fluid in early Alzheimer disease. J Biol Chem (2011) 3.57
Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study. Lancet Neurol (2012) 3.48
Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry (2012) 2.68
Delirium is a strong risk factor for dementia in the oldest-old: a population-based cohort study. Brain (2012) 2.64
Chitinase enzyme activity in CSF is a powerful biomarker of Alzheimer disease. Neurology (2012) 2.23
Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurol (2012) 2.22
Inflammation and neurodegenerative diseases. Am J Clin Nutr (2006) 1.76
Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease. Arch Neurol (2012) 1.66
Region-specific hierarchy between atrophy, hypometabolism, and β-amyloid (Aβ) load in Alzheimer's disease dementia. J Neurosci (2012) 1.48
The synaptic accumulation of hyperphosphorylated tau oligomers in Alzheimer disease is associated with dysfunction of the ubiquitin-proteasome system. Am J Pathol (2012) 1.36
Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures. Arch Neurol (2012) 1.32
miR-206 regulates brain-derived neurotrophic factor in Alzheimer disease model. Ann Neurol (2012) 1.32
Age and diagnostic performance of Alzheimer disease CSF biomarkers. Neurology (2012) 1.31
Injury markers predict time to dementia in subjects with MCI and amyloid pathology. Neurology (2012) 1.16
Proteomic changes in cerebrospinal fluid of presymptomatic and affected persons carrying familial Alzheimer disease mutations. Arch Neurol (2012) 0.97
Discovery of AZD3839, a potent and selective BACE1 inhibitor clinical candidate for the treatment of Alzheimer disease. J Biol Chem (2012) 0.96
Evaluation of plasma proteomic data for Alzheimer disease state classification and for the prediction of progression from mild cognitive impairment to Alzheimer disease. Alzheimer Dis Assoc Disord (2013) 0.90
Comparison of clinical characteristics between familial and non-familial early onset Alzheimer's disease. J Neurol (2012) 0.87
Executive dysfunction in frontotemporal dementia is related to abnormalities in frontal white matter tracts. J Neurol (2011) 0.87
Epigenetic regulation of BACE1 in Alzheimer's disease patients and in transgenic mice. Neuroscience (2012) 0.86
Stereotypic behaviors in degenerative dementias. J Neurol (2012) 0.77
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. Lancet Neurol (2007) 3.22
A polymorphism in CALHM1 influences Ca2+ homeostasis, Abeta levels, and Alzheimer's disease risk. Cell (2008) 2.55
Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition. Proc Natl Acad Sci U S A (2008) 2.44
SQSTM1 mutations in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Neurology (2012) 2.06
Molecular mechanisms involved in lymphocyte recruitment in inflamed brain microvessels: critical roles for P-selectin glycoprotein ligand-1 and heterotrimeric G(i)-linked receptors. J Immunol (2002) 1.88
The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement (2011) 1.87
Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease. Arch Neurol (2005) 1.82
Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease. Arch Neurol (2006) 1.79
Vascular endothelial growth factor gene variability is associated with increased risk for AD. Ann Neurol (2005) 1.66
MicroRNA and mRNA expression profile screening in multiple sclerosis patients to unravel novel pathogenic steps and identify potential biomarkers. Neurosci Lett (2011) 1.64
Autosomal dominant frontotemporal lobar degeneration due to the C9ORF72 hexanucleotide repeat expansion: late-onset psychotic clinical presentation. Biol Psychiatry (2013) 1.58
Intrathecal levels of IL-6, IL-11 and LIF in Alzheimer's disease and frontotemporal lobar degeneration. J Neurol (2008) 1.53
Serum MCP-1 levels are increased in mild cognitive impairment and mild Alzheimer's disease. Neurobiol Aging (2005) 1.52
An APOE haplotype associated with decreased ε4 expression increases the risk of late onset Alzheimer's disease. J Alzheimers Dis (2011) 1.45
RhoA and zeta PKC control distinct modalities of LFA-1 activation by chemokines: critical role of LFA-1 affinity triggering in lymphocyte in vivo homing. Immunity (2004) 1.42
Identification of soluble TREM-2 in the cerebrospinal fluid and its association with multiple sclerosis and CNS inflammation. Brain (2008) 1.38
Prolonged visual memory enhancement after direct current stimulation in Alzheimer's disease. Brain Stimul (2011) 1.34
Chemokines in serum and cerebrospinal fluid of Alzheimer's disease patients. Ann Neurol (2003) 1.28
Plasma levels of beta-amyloid (1-42) in Alzheimer's disease and mild cognitive impairment. Neurobiol Aging (2006) 1.23
The CALHM1 P86L polymorphism is a genetic modifier of age at onset in Alzheimer's disease: a meta-analysis study. J Alzheimers Dis (2010) 1.19
Oxidative imbalance in patients with mild cognitive impairment and Alzheimer's disease. Neurobiol Aging (2005) 1.15
Expression and genetic analysis of miRNAs involved in CD4+ cell activation in patients with multiple sclerosis. Neurosci Lett (2011) 1.15
Efficacy of Souvenaid in mild Alzheimer's disease: results from a randomized, controlled trial. J Alzheimers Dis (2012) 1.11
Early onset behavioral variant frontotemporal dementia due to the C9ORF72 hexanucleotide repeat expansion: psychiatric clinical presentations. J Alzheimers Dis (2012) 1.11
Optimal plasma progranulin cutoff value for predicting null progranulin mutations in neurodegenerative diseases: a multicenter Italian study. Neurodegener Dis (2011) 1.05
Selective DNA methylation of BDNF promoter in bipolar disorder: differences among patients with BDI and BDII. Neuropsychopharmacology (2012) 1.04
Progranulin plasma levels as potential biomarker for the identification of GRN deletion carriers. A case with atypical onset as clinical amnestic Mild Cognitive Impairment converted to Alzheimer's disease. J Neurol Sci (2009) 1.03
Disease-modifying treatments for Alzheimer's disease. Ther Adv Neurol Disord (2011) 1.03
MCP-1 in Alzheimer's disease patients: A-2518G polymorphism and serum levels. Neurobiol Aging (2004) 1.02
Loss of function mutations in the progranulin gene are related to pro-inflammatory cytokine dysregulation in frontotemporal lobar degeneration patients. J Neuroinflammation (2011) 1.02
Osteopontin is increased in the cerebrospinal fluid of patients with Alzheimer's disease and its levels correlate with cognitive decline. J Alzheimers Dis (2010) 1.01
Efficient recruitment of lymphocytes in inflamed brain venules requires expression of cutaneous lymphocyte antigen and fucosyltransferase-VII. J Immunol (2005) 1.00
Rs5848 variant influences GRN mRNA levels in brain and peripheral mononuclear cells in patients with Alzheimer's disease. J Alzheimers Dis (2009) 1.00
Evidence of the association of BIN1 and PICALM with the AD risk in contrasting European populations. Neurobiol Aging (2011) 1.00
Is M129V of PRNP gene associated with Alzheimer's disease? A case-control study and a meta-analysis. Neurobiol Aging (2005) 0.99
Absence of TREM2 polymorphisms in patients with Alzheimer's disease and Frontotemporal Lobar Degeneration. Neurosci Lett (2006) 0.98
Production of monocyte chemoattractant protein-1 in amyotrophic lateral sclerosis. Muscle Nerve (2005) 0.97
Immunological patterns identifying disease course and evolution in multiple sclerosis patients. J Neuroimmunol (2005) 0.97
Role of hnRNP-A1 and miR-590-3p in neuronal death: genetics and expression analysis in patients with Alzheimer disease and frontotemporal lobar degeneration. Rejuvenation Res (2011) 0.97
Immunoproteasome LMP2 60HH variant alters MBP epitope generation and reduces the risk to develop multiple sclerosis in Italian female population. PLoS One (2010) 0.97
Phenotypic heterogeneity of the GRN Asp22fs mutation in a large Italian kindred. J Alzheimers Dis (2011) 0.97
Decreased circulating miRNA levels in patients with primary progressive multiple sclerosis. Mult Scler (2013) 0.96
MicroRNAs as active players in the pathogenesis of multiple sclerosis. Int J Mol Sci (2012) 0.96
Multiple sclerosis: BAFF and CXCL13 in cerebrospinal fluid. Mult Scler (2011) 0.95
Expression of the transcription factor Sp1 and its regulatory hsa-miR-29b in peripheral blood mononuclear cells from patients with Alzheimer's disease. J Alzheimers Dis (2013) 0.94
A functional variant in ERAP1 predisposes to multiple sclerosis. PLoS One (2012) 0.93
Genetics of frontotemporal lobar degeneration. Front Neurol (2012) 0.92
Innate immune system and inflammation in Alzheimer's disease: from pathogenesis to treatment. Neuroimmunomodulation (2014) 0.92
Macrophage infiltration and death in the nerve during the early phases of experimental diabetic neuropathy: a process concomitant with endoneurial induction of IL-1beta and p75NTR. J Neurol Sci (2002) 0.92
Genetics and biology of Alzheimer's disease and frontotemporal lobar degeneration. Int J Clin Exp Med (2010) 0.91
Expression and Genetic Analysis of MicroRNAs Involved in Multiple Sclerosis. Int J Mol Sci (2013) 0.91
Inflammation and oxidative damage in Alzheimer's disease: friend or foe? Front Biosci (Schol Ed) (2011) 0.91
Founder effect and estimation of the age of the Progranulin Thr272fs mutation in 14 Italian pedigrees with frontotemporal lobar degeneration. Neurobiol Aging (2010) 0.91
Progress in Alzheimer's disease. J Neurol (2011) 0.90
Progranulin genetic variations in frontotemporal lobar degeneration: evidence for low mutation frequency in an Italian clinical series. Neurogenetics (2008) 0.90
VEGF genetic variability is associated with increased risk of developing Alzheimer's disease. J Neurol Sci (2009) 0.89
Interleukin-1 beta and interferon-gamma induce proliferation and apoptosis in cultured Schwann cells. J Neuroimmunol (2002) 0.89
The impact of osteopontin gene variations on multiple sclerosis development and progression. Clin Dev Immunol (2012) 0.89
Replication study to confirm the role of CYP2D6 polymorphism rs1080985 on donepezil efficacy in Alzheimer's disease patients. J Alzheimers Dis (2012) 0.88
Interleukin-6 plasma level increases with age in an Italian elderly population ("The Treviso Longeva"-Trelong-study) with a sex-specific contribution of rs1800795 polymorphism. Age (Dordr) (2009) 0.88
From genotype to phenotype: two cases of genetic frontotemporal lobar degeneration with premorbid bipolar disorder. J Alzheimers Dis (2011) 0.88
Cerebrospinal fluid biomarkers in Progranulin mutations carriers. J Alzheimers Dis (2011) 0.88
Inverse agonism of cannabinoid CB1 receptor blocks the adhesion of encephalitogenic T cells in inflamed brain venules by a protein kinase A-dependent mechanism. J Neuroimmunol (2011) 0.88
Screening of the PFN1 gene in sporadic amyotrophic lateral sclerosis and in frontotemporal dementia. Neurobiol Aging (2012) 0.87
Alzheimer's disease: from pathogenesis to disease-modifying approaches. CNS Neurol Disord Drug Targets (2011) 0.86
Presenilin-1 mutation E318G and familial Alzheimer's disease in the Italian population. Neurobiol Aging (2006) 0.85
A novel polymorphism in SEL1L confers susceptibility to Alzheimer's disease. Neurosci Lett (2006) 0.85
Possible influence of a non-synonymous polymorphism located in the NGF precursor on susceptibility to late-onset Alzheimer's disease and mild cognitive impairment. J Alzheimers Dis (2012) 0.85
Inflammation in neurodegenerative disorders: friend or foe? Curr Aging Sci (2008) 0.84
CCR2-64I polymorphism and CCR5Delta32 deletion in patients with Alzheimer's disease. J Neurol Sci (2004) 0.84
Frontotemporal lobar degeneration: current knowledge and future challenges. J Neurol (2012) 0.84
The H1 haplotype of the tau gene (MAPT) is associated with mild cognitive impairment. J Alzheimers Dis (2010) 0.84
The SIRT2 polymorphism rs10410544 and risk of Alzheimer's disease in two Caucasian case-control cohorts. Alzheimers Dement (2012) 0.83
GRN variability contributes to sporadic frontotemporal lobar degeneration. J Alzheimers Dis (2010) 0.83
Epigenetic regulation of fatty acid amide hydrolase in Alzheimer disease. PLoS One (2012) 0.83
Chemokine network in multiple sclerosis: role in pathogenesis and targeting for future treatments. Expert Rev Neurother (2004) 0.83
CHF5074 reduces biomarkers of neuroinflammation in patients with mild cognitive impairment: a 12-week, double-blind, placebo-controlled study. Curr Alzheimer Res (2013) 0.83
Absence of cerebrospinal fluid oligoclonal bands is associated with delayed disability progression in relapsing-remitting MS patients treated with interferon-beta. J Neurol Sci (2006) 0.83
ICOS gene haplotypes correlate with IL10 secretion and multiple sclerosis evolution. J Neuroimmunol (2007) 0.82
Alpha1-antichymotrypsin induces TNF-alpha production and NF-kappaB activation in the murine N9 microglial cell line. Neurosci Lett (2009) 0.82
Progranulin gene (GRN) promoter methylation is increased in patients with sporadic frontotemporal lobar degeneration. Neurol Sci (2012) 0.82
An emerging role for long non-coding RNA dysregulation in neurological disorders. Int J Mol Sci (2013) 0.82
Absence of TARDBP gene mutations in an italian series of patients with frontotemporal lobar degeneration. Dement Geriatr Cogn Disord (2009) 0.82
Cerebrospinal fluid progranulin levels in patients with different multiple sclerosis subtypes. Neurosci Lett (2009) 0.82
Regulatory T cells suppress the late phase of the immune response in lymph nodes through P-selectin glycoprotein ligand-1. J Immunol (2013) 0.82
Candidate gene analysis of IP-10 gene in patients with Alzheimer's disease. Neurosci Lett (2006) 0.81
Gender-specific influence of the chromosome 16 chemokine gene cluster on the susceptibility to Multiple Sclerosis. J Neurol Sci (2007) 0.81
Influence of the Glu298Asp polymorphism of NOS3 on age at onset and homocysteine levels in AD patients. Neurobiol Aging (2005) 0.81
GSK3β genetic variability in patients with Multiple Sclerosis. Neurosci Lett (2011) 0.81
Identification of a new susceptibility variant for multiple sclerosis in OAS1 by population genetics analysis. Hum Genet (2011) 0.81
Does vascular burden contribute to the progression of mild cognitive impairment to dementia? Dement Geriatr Cogn Disord (2012) 0.81
Association of HLA class I markers with multiple sclerosis in the Italian and UK population: evidence of two independent protective effects. J Med Genet (2011) 0.80
Progranulin gene variability and plasma levels in bipolar disorder and schizophrenia. PLoS One (2012) 0.80
Heterosexual pedophilia in a frontotemporal dementia patient with a mutation in the progranulin gene. Biol Psychiatry (2011) 0.80
Gender effects on plasma PGRN levels in patients with Alzheimer's disease: a preliminary study. J Alzheimers Dis (2013) 0.80
Loss of epidermal growth factor regulation by cobalamin in multiple sclerosis. Brain Res (2010) 0.80
The T-786C NOS3 polymorphism in Alzheimer's disease: association and influence on gene expression. Neurosci Lett (2005) 0.80
Inducible nitric oxide synthase (iNOS) in immune-mediated demyelination and Wallerian degeneration of the rat peripheral nervous system. Exp Neurol (2004) 0.80